Physician profile
Keith Craley
NPI 1720034036
$2,184.27
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $571 · 2022: $755 · 2023: $843 · 2024: $15.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843 · Education: $15.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.51 |
| Education | $15.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $588.45 | 2021-2024 | Breztri, Tezspire, Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $484.30 | 2021-2023 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Actelion Pharmaceuticals US, INC. | $160.41 | 2021-2023 | Opsumit, Uptravi |
| Harmony Biosciences LLC | $151.67 | 2022-2023 | Wakix |
| Philips North America LLC | $85.15 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $75.83 | 2022-2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $67.26 | 2021-2023 | Aralast |
| Baxter Healthcare | $54.77 | 2022-2023 | Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
| Ambu INC. | $54.07 | 2022-2023 | |
| United Therapeutics Corporation | $51.70 | 2022-2023 | |
| Glaxosmithkline, LLC. | $47.99 | 2022-2023 | Nucala |
| Inspire Medical Systems, INC. | $42.36 | 2023 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $38.01 | 2023 | Eliquis |
| Advanced Respiratory, INC | $34.31 | 2021 | |
| Jazz Pharmaceuticals INC. | $32.15 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $29.53 | 2022-2023 | Yupelri |
| Pharming Healthcare, INC. | $28.19 | 2022 | |
| Amgen INC. | $26.65 | 2023 | Tezspire |
| Paratek Pharmaceuticals, INC. | $24.43 | 2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $22.43 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.78 | 2023 | Ultomiris |
| Vapotherm INC | $19.16 | 2021 | |
| Phadia US INC. | $16.95 | 2023 | Immunocap |
| Grifols USA, LLC | $13.55 | 2023 | Prolastin-C Liquid |
| Genzyme Corporation | $13.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Craley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.